Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Verastem, Inc.

WSW, NY, September 25th, 2026, FinanceWire Three months ago, Nuvectis Pharma (NASDAQ:NVCT) was an oncology developer anchored by a single early-sta...

Nuvectis’ In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It’s Not Even Their Lead Asset

H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating on Verastem today and set a price target of $18.00. According to TipRanks, Y. M...

Verastem (VSTM) Receives a Buy from H.C. Wainwright

RBC Capital analyst Leonid Timashev maintained a Buy rating on Verastem on September 16 and set a price target of $14.00. The company’s shares clos...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	VSTM	$7.77	-0.45%	482.01K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	VSTM	$7.77	-0.4%	482.01K
3
4
5
6

VSTM

Get Verastem, Inc. Data in Excel

Get Verastem, Inc. Data in Excel